Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Share News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 47.00
Bid: 46.00
Ask: 48.00
Change: 1.70 (3.91%)
Spread: 2.00 (4.348%)
Open: 43.50
High: 47.50
Low: 45.00
Prev. Close: 43.50
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS: Morrisons Sales Decline Sinks Shares

Thu, 07th May 2015 10:26

LONDON (Alliance News) - The following stocks are amongst the biggest risers and fallers within the main London indices midday Thursday.
-------
FTSE 100 WINNERS
-------
RSA Insurance Group, up 1.2%. The insurer cautioned that lower interest rates and currency moves in its vital areas of business are having an unwelcome effect on business, but said its net profit in the first quarter of 2015 was "a little ahead" of plans and included gains it is expecting to make on asset sales.

EasyJet, up 0.3%. The airline said it flew 6.0 million passengers in April, up from 5.8 million a year earlier, while its load factor, a measure of how many paid seats are filled on its planes, rose to 90.8% from 89.8%. For the 12 months to the end of April, it flew 66.2 million passengers, up from 62.4 million in the previous 12 months, while its load factor improved to 91.0% from 89.7%. The increase came despite easyJet cancelling 602 flights in April compared with 48 a year earlier, mainly due to air traffic control strikes in France.
-------
FTSE 100 LOSERS
-------
WM Morrison Supermarkets, down 6.8%. The supermarket chain reported a drop in sales in its first quarter but said the company's financial position remains "strong" as it predicted higher profit in the second half of its financial year than in the first. The grocer said total sales in the 13 weeks to May 3 were down 5.1% on the same period a year earlier, while like-for-like sales were down 6.6%.

Admiral Group, down 4.5%, G4S, down 3.6%, and BP, down 2.7%. The stocks are down after going ex-dividend, meaning new buyers no longer qualify for the latest dividend payouts.

Barclays, down 2.4%. Four big banks are expected to plead guilty to rigging foreign-currency exchange rates and pay billions in combined penalties as part of settlement agreements expected to be announced as early as next week, the Wall Street Journal reported citing people familiar with the matter. The report indicated that US prosecutors are preparing to announce separate settlements simultaneously with Citigroup Inc, Barclays, JPMorgan Chase & Co and The Royal Bank of Scotland Group.
-------
FTSE 250 WINNERS
-------
Telecity Group, up 19%. The company said it has received a takeover approach from American data-centre provider Equinix Inc, a few months after agreeing an all-share deal to acquire data-centre services provider Interxion Holding NV. Telecity also reiterated its guidance for 2015. Equinix has approached with a potential offer of 1,145 pence per share, payable in a mixture of cash and stock in Equinix. Around 54% of the consideration would be payable in cash, and 46% in Equinix stock. Telecity currently trades at 1,066.50p.

Esure Group, up 1.2%. The insurer said it increased motor gross written premiums in the first quarter of 2015 and made some progress on its pricing. It said total gross written premiums increased to GBP130.7 million in the three months ended March 31, compared with GBP123.5 million in the corresponding quarter of the prior year. In-force policies increased to 1.971 million from 1.962 million at the same stage of the prior year. Additional services revenue was down 1.2% to GBP23.4 million.
-------
FTSE 250 LOSERS
-------
Henderson Group, down 4.4%, Morgan Advanced Materials, down 3.9%, Acacia Mining, down 3.6%, and Rightmove, down 3.2%. The stocks have gone ex-dividend.

Millennium & Copthorne, down 4.2%. The hotels operator reported lower profit in its first quarter, despite a rise in revenue and in revenue per available room, as profit was hit by labour cost pressures and a tough comparative in 2014. It said pretax profit in the three months to March 31 declined to GBP19 million from GBP20 million the year before. This was despite an increase in revenue to GBP189 million from GBP175 million and a rise in revenue per available room to GBP61.60 from GBP58.23.

IMI, down 4.1%. The engineering company said its market conditions remained challenging in the first quarter of 2015 and said its revenue dropped on the back of foreign exchange movements and contract delays. IMI said its revenue in the first quarter to the end of March was down 4% year-on-year, reflecting the ongoing damage to its results from the strength of sterling, though this was partially offset by an initial contribution from German power valve company Bopp & Reuther, which it acquired in 2014.
-------
AIM ALL-SHARE WINNERS
-------
Sareum Holdings, up 20%. The cancer drug discovery and development company said its equity swap deal with YA Global Master SPV Ltd has concluded ahead of schedule. Sareum said YA Global Master will remain an ordinary shareholder in the company, with a 1.15% stake, but said there are no further obligations under the equity swap agreement.

Stellar Diamonds, up 16%. The company said it will hold its next diamond sale of up to 4,439 carats from trial mining at the Baoulé kimberlite project in Guinea in Dubai and Antwerp via the eDiamond auction platform this month. Stellar said the sale will include gem quality stones of up to 12.6 carats in size and is part of its anticipated regular sales process from Baoulé, where it is targeting a total of 15,000 carats in order to establish the diamond grade at the project.

Tiziana Life Sciences, up 14%. The company said it has licensed from Cardiff University scientists a new anti-cancer stem cell agent capable of targeting aggressive tumours forming from cells originating in the breast, pancreas, colon and prostate.

ValiRx, up 7.4%. The life sciences company said it has signed a contract with bioanalytical chemistry and research company Admescope Ltd for access to the TRAC Finnish gene expression and biomarker technology. ValiRx acquired the assets and intellectual property rights of TRAC at the start of 2015. Under the agreement, on which no financial details were disclosed, Admescope will licence the TRAC technology for its toxicological testing services unit.
-------
AIM ALL-SHARE LOSERS
-------
African Copper, off 84%. The company said it will seek approval from shareholders to cancel its trading on AIM and in Botswana at a general meeting to be held towards the end of May due to the company's size and lack of liquidity, a proposition that has already gained support from the company's largest shareholders. It said it is suffering from a "lack of demand" for its shares which is making it difficult to use the listings to raise money from investors, adding that the "low liquidity" in the company's shares could lead to "volatility" in the share price.

MXC Capital, down 17%. The merchant bank said it has raised GBP11.7 million after expenses in a placing of 480.0 million new share priced at 2.5 pence each. In a statement, it said it will use the money raised and cash it already has to "pursue a number of near-term, identified opportunities and further develop a growing pipeline of future opportunities". The company's shares currently trade at 3.173p.

Red Rock Resources, down 16%. The gold explorer said it has moved to protect its interests in Kenya after the country's Ministry of Mining told the company's local partner that it had terminated two special licenses, although it warned that it may have to book a further writedown on its Kenyan assets if it doesn't get a positive result quickly.

Asian Citrus Holdings, down 11%. The company said it expects the 2015 winter harvest from its Xinfeng Plantation to be significantly reduced compared with the previous year, which in turn will have a knock-on effect for its results in the year to end-June 2016, as it tackles Huanglongbing disease amongst its orange trees.
-------

By Neil Thakrar; neilthakrar@alliancenews.com; @NeilThakrar1

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
5 May 2023 15:53

Sareum gets approval for phase one psoriasis studies in Australia

(Sharecast News) - Biotechnology developer Sareum Holdings announced on Friday that it has been granted approval by Australia's Therapeutic Goods Administration (TGA) to conduct phase one clinical studies on SDC-1801.

Read more
5 May 2023 11:26

Sareum receives Australian approval for psoriasis drug clinical trial

Alliance News) - Sareum Holdings PLC on Friday said its application to start a phase 1 clinical trial in Australia of its lead product, psoriasis drug SDC-1801, has been approved.

Read more
5 May 2023 11:11

AIM WINNERS & LOSERS: Aptamer says struggling to convert pipeline

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more
22 Mar 2023 11:47

Sareum Holdings interim loss widens as touts psoriasis candidate drug

(Alliance News) - Sareum Holdings PLC on Wednesday reported an increased half-year loss for the six months to December 31, as it continued to work on its psorasis candidate drug SDC-1801.

Read more
17 Mar 2023 18:06

IN BRIEF: Sareum makes trial application for SDC-1801 in Australia

Sareum Holdings PLC - Cambridge-based biotechnology company developing kinase inhibitors for autoimmune disease and cancer - On Wednesday, says it has begun an application to perform phase one clinical studies on SDC-1801 in Australia under the clinical trial notification scheme.

Read more
15 Mar 2023 15:43

UK earnings, trading statements calendar - next 7 days

Thursday 16 March 
Capital LtdFull Year Results
Centamin PLCFull Year Results
Deliveroo PLCFull Year Results
DFS Furniture PLCHalf Year Results
Empiric Student Property PLCFull Year Results
Eurocell PLCFull Year Results
FW ThorpeHalf Year Results (TBC)
Gelion PLCHalf Year Results
Gem Diamonds LtdFull Year Results
Gym Group PLCFull Year Results
Halma PLCTrading Statement
Helios Towers PLCFull Year Results
Hostmore PLCFull Year Results
Investec PLC and LtdTrading Statement
National World PLCFull Year Results
OSB Group PLCFull Year Results
PensionBee Group PLCFull Year Results
Polymetal International PLCfull Year Results
PYX Resources LtdFull Year Results
Rentokil Initial PLCFull Year Results
Restore PLCFull Year Results
Savills PLCFull Year Results
TI Fluid Systems PLCFull Year Results
WAG Payment Solutions PLCFull Year Results
Friday 17 March 
no events scheduled 
Monday 20 March 
Jubilee Metals Group PLCHalf Year Results
Tuesday 21 March 
Alliance Pharma PLCFull Year Results
Aptitude Software Group PLCFull Year Results
Boku IncFull Year Results
Diversified Energy Co PLCFull Year Results
Ergomed PLCFull Year Results
Fintel PLCFull Year Results
Gamma Communications PLCFull Year Results
Henry Boot PLCFull Year Results
Kape Technologies PLCFull Year Results
Kingfisher PLCFull Year Results
Luceco PLCFull Year Results
MP Evans Group PLCFull Year Results
Ocado Group PLCTrading Statement
Oxford Nanopore Technologies PLCFull Year Results
Pebble Group PLCFull Year Results
Quixant PLCFull Year Results
ScS Group PLCHalf Year Results
SThree PLCTrading Statement
Staffline Group PLCFull Year Results
Tissue Regenix Group PLCFull Year Results
Trustpilot Group PLCFull Year Results
YouGov PLCHalf Year Results
Zotefoams PLCFull Year Results
Wednesday 22 March 
Anpario PLCFull Year Results
Atalaya Mining PLCFull Year Results
BioPharma Credit PLCFull Year Results
Blackbird PLCFull Year Results
Bloomsbury Publishing PLCTrading Statement
Essentra PLCFull Year Results
Fevertree Drinks PLCFull Year Results
Genel Energy PLCFull Year Results
Gresham House PLCFull Year Results
Hostelworld Group PLCFull Year Results
Judges Scientific PLCFull Year Results
Kenmare Resources PLCFull Year Results
LSL Property Services PLCFull Year Results
Mpac Group PLCFull Year Results
NAHL Group PLCFull Year Results
Pendragon PLCFull Year Results
Pharos Energy PLCFull Year Results
Sareum Holdings PLCHalf Year Results
Ten Entertainment Group PLCFull Year Results
Tribal Group PLCFull Year Results
Vistry Group PLCFull Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved. 

Read more
6 Mar 2023 16:16

Sareum looks at options as GSK division returns cancer drug candidate

(Sharecast News) - Biotechnology developer Sareum announced on Monday that GSK subsidiary Sierra Oncology has returned clinical study reports and associated documents related to 'SRA737' to Sareum's co-development partner, the CRT Pioneer Fund.

Read more
6 Mar 2023 11:19

Sareum says GSK's Sierra returns clinical study reports to CRT Pioneer

(Alliance News) - Sareum Holdings PLC on Monday said that GSK PLC subsidiary Sierra Oncology Inc has completed the return of the clinical study reports relating to SRA737 to Sarerum's co-development partner CRT Pioneer Fund LP.

Read more
16 Dec 2022 21:53

TRADING UPDATES: Dev Clever to cancel shares; Tintra raises funds

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
16 Dec 2022 16:55

Sareum confident despite recent setbacks

(Sharecast News) - Autoimmune and cancer-focussed biotechnology company Sareum said in an update on Friday that it remained "confident" despite some recent setbacks.

Read more
16 Dec 2022 10:44

AIM WINNERS & LOSERS: Time Finance jumps on strong first-half results

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more
9 Dec 2022 15:43

UK shareholder meetings calendar - next 7 days

Monday 12 December 
Devolver Digital IncSGM re 2022 Long-Term Incentive Plan approval
Marwyn Value Investors LtdAGM
Osirium Technologies PLCGM re placing agreement with Allenby Capital
PCF Group PLCGM re proposed cancellation of trading on AIM
Tuesday 13 December 
Amedeo Air Four Plus LtdAGM
Avation PLCAGM
Blancco Technology Group PLCAGM
JD Sports Fashion PLCGM re remuneration policy
Macau Property Opportunities Fund LtdAGM
Softcat PLCAGM
Spectris PLCGM re remuneration policy
Wednesday 14 December 
Fidelity Special Values PLCAGM
Kistos PLCGM re new non-operational entity
Parsley Box Group PLCGM re proposal to become a private limited company
TP Group PLCGM re cash acquisition
Volution Group PLCAGM
Westpac Banking CorpAGM
Thursday 15 December 
Aeorema Communications PLCAGM
Argos Resources LtdAGM
Baillie Gifford Japan Trust PLCAGM
Capricorn Energy PLCGM re proposed share premium account cancellation
Chelverton Growth Trust PLCAGM
CQS Natural Resources Growth & Income PLCAGM
DX Group PLCAGM
DXS International PLCAGM
Glenveagh Properties PLCEGM
Secured Income Fund PLCGM re proposed reduction of capital
Schroder Income Growth Fund PLCAGM
Friday 16 December 
Bellway PLCAGM
Inchcape PLCGM re Derco acquisition
JPMorgan Global Growth & Income PLCGM re proposed combination with JPMorgan Elect PLC
National Australia Bank LtdAGM
Sareum Holdings PLCAGM
Thor Explorations LtdAGM
UP Global Sourcing Holdings PLCAGM
  
Copyright 2022 Alliance News Ltd. All Rights Reserved.

Read more
21 Nov 2022 12:44

IN BRIEF: Sareum salutes publication of SRA737 combination trial data

Sareum Holdings PLC - Cambridge, England-based biotechnology company focused on developing kinase inhibitors for autoimmune disease & cancer - Says it is pleased by the publication of data from the Phase 1/2 trial of SRA737 as a combination treatment for advanced cancers in the medical journal, Clinical Cancer Research.

Read more
24 Oct 2022 10:28

IN BRIEF: Sareum widens annual loss; considers future of SRA737

Sareum Holdings PLC - Cambridge, England-based drug developer for cancer and autoimmune diseases - In the year ended June 30, pretax loss widens to GBP2.6 million from GBP1.7 million a year before. No revenue is recorded in either year, but in the previous year it brought in GBP171,000 in other operating income, with none recorded for financial 2022. Says it will discuss the future of SRA737 with partner Cancer Research Technology Pioneer Fund. Earlier this month, GSK PLC subsidiary Sierra Oncology Inc said it intends to return the rights for the SRA737 cancer treatment to CPF.

Read more
12 Oct 2022 10:47

Sareum plunges as GSK subsidiary Sierra returns rights for SRA737

(Alliance News) - Sareum Holdings PLC on Wednesday after Sierra Oncology Inc, a subsidiary of GSK PLC, said it intends to return the rights for SRA737 to the CRT Pioneer Fund LP.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.